Flame Biosciences searches for future after Novartis flunks on canakinumab
Flame Biosciences debuted with the idea that its monoclonal antibody that inhibits IL-1ß, a key cytokine in inflammation, would be effective at reducing cancer.
But the Pennsylvania biotech flashed the yellow lights on testing that hypothesis last year because it wanted to see if a Big Pharma could prove it first. Novartis failed — again and again and again. The Swiss giant’s canakinumab got the FDA no-go back in 2018 for cardio risk reduction, but Novartis thought the drug would work in oncology.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.